Cited by 211Parkinson's Disease Mechanisms and TreatmentsCoenzyme Q10 studies and effectsAntioxidant Activity and Oxidative Stress

The DOI matches its Crossref record; 13 of the 14 references it cites were found in a registry or an index.

A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease

Fahn, Stanley·1992·Annals of Neurology

DOI 10.1002/ana.410320722

Open this paper in CoChat — free account

Abstract

High dosages of a combination of alpha-tocopherol and ascorbate were administered to patients with early Parkinson's disease as an open-labeled trial and pilot study to test the endogenous toxic hypothesis of the etiology of Parkinson's disease. Patients receiving concomitant amantadine and anticholinergics were allowed to participate, but those receiving levodopa or dopamine agonists were not. The study was begun prior to the availability of deprenyl. The primary end point of the trial was progression of the disease until patients needed treatment with levodopa or a dopamine agonist. The time when levodopa became necessary in the treated patients was compared to another group of patients followed elsewhere who did not receive antioxidants. The time when levodopa became necessary was extended by 2.5 years in the group receiving alpha-tocopherol and ascorbate. Results of this pilot study suggest that the progression of Parkinson's disease may be slowed by administration of these antioxidants. Controlled clinical trials using double-blind randomization techniques are required to confirm these results.

Integrity signals

Registry

Crossref · 10.1002/ana.410320722

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,925
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212004 · Cited by 912
Third symposium on Parkinson's disease
Tucker, J. S. (1970) · Electroencephalography and Clinical Neurophysiology · doi:10.1016/0013-4694(70)90108-2 · Cited by 416
DATATOP: A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
(1989) · Archives of Neurology · doi:10.1001/archneur.1989.00520460028009 · Cited by 357
Catecholamine toxicity: a proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease.
Dg, G. (1984) · PubMed · Cited by 292
Possible role of neuromelanin in the pathogenesis of Parkinson's disease
Mann, D. M. A., & Yates, P. O. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90074-x · Cited by 211
Monoamines, noyaux gris centraux et syndrome de Parkinson
Stern, G. M. (1975) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(75)90147-1 · Cited by 134
Effect of High Doses of Dietary Vitamin E on the Concentrations of Vitamin E in Several Brain Regions, Plasma, Liver, and Adipose Tissue of Rats
Vatassery, G. T., Brin, M. F., Fahn, S., Kayden, H. J., & Traber, M. G. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb01083.x · Cited by 106
Self-citation
Should Levodopa Therapy for Parkinsonism be Started Early or Late? Evidence Against Early Treatment
Fahn, S., & Bressman, S. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046412 · Cited by 101
Self-citation
An open trial of high-dosage antioxidants in early Parkinson's disease
Fahn, S. (1991) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/53.1.380s · Cited by 90
Self-citation

Show all 14 references

Research works printed but not linked: 3

Cohen, 1983, Neural Transm, 19, 89
Graham, 1984, Neurotoxicology, 5, 83
Olanow, 1990, Neurology, 40, 32

Sorted by citations

Reactive Oxygen Species, Toxicity, Oxidative Stress, and Antioxidants: Chronic Diseases and Aging
Jomova, K., Raptova, R., Alomar, S. Y., Alwasel, S. H., Nepovimova, E., Kuca, K., & Valko, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03562-9 · Cited by 2,638
The Role of Oxidative Stress in Parkinson's Disease
Dias, V., Junn, E., & Mouradian, M. M. (2013) · Journal of Parkinson’s Disease · doi:10.3233/jpd-130230 · Cited by 1,845
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications
Liu, Z., Zhou, T., Ziegler, A. C., Dimitrion, P., & Zuo, L. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/2525967 · Cited by 810
Oxidative processes and antioxidative defense mechanisms in the aging brain 1
Reiter, R. J. (1995) · The FASEB Journal · doi:10.1096/fasebj.9.7.7737461 · Cited by 801
Oxidative Stress and Antioxidants in Neurodegenerative Disorders
Olufunmilayo, E. O., Gerke-Duncan, M. B., & Holsinger, R. M. D. (2023) · Antioxidants · doi:10.3390/antiox12020517 · Cited by 752
Epidemiology of parkinson’s disease
Tanner, C. M., & Goldman, S. M. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70259-0 · Cited by 640
Oxidative stress: Free radical production in neural degeneration
Götz, M. E., Künig, G., Riederer, P. F., & Youdim, M. B. H. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90055-8 · Cited by 482
Advances in the treatment of Parkinson's disease
Singh, N., Pillay, V., & Choonara, Y. E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.11.009 · Cited by 398
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes
Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 373
The Role of Oxidative Stress in Parkinson’s Disease
Chang, K., & Chen, C. (2020) · Antioxidants · doi:10.3390/antiox9070597 · Cited by 369
Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies
Elfawy, H. A., & Das, B. B. (2018) · Life Sciences · doi:10.1016/j.lfs.2018.12.029 · Cited by 348
Glutathione: Systemic Protectant Against Oxidative and Free Radical Damage
Kidd, P. M. (1997) · Cited by 267
Vitamin E and Alzheimer disease: the basis for additional clinical trials
Grundman, M. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.630s · Cited by 269
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 255
Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): [RETIRED]
Suchowersky, O., Gronseth, G., Perlmutter, J. S., Reich, S. G., Zesiewicz, T., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000206363.57955.1b · Cited by 241
Neurobehavioral aspects of antioxidants in aging
Cantuti‐Castelvetri, I., Shukitt‐Hale, B., & Joseph, J. A. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00008-3 · Cited by 233
The emerging role of nutrition in Parkinson's disease
Seidl, S. E., Santiago, J. A., Bilyk, H. T., & Potashkin, J. A. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00036 · Cited by 218
Glutathione and Parkinson's disease: Is this the elephant in the room?
Zeevalk, G. D., Razmpour, R., & Bernard, L. P. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.01.017 · Cited by 217
Diet and Parkinson's disease II
Hellenbrand, W., Boeing, H., Robra, B., Seidler, A., Vieregge, P., NISCHAN, P., Joerg, J., Oertel, W. H., Schneider, E., & Ulm, G. (1996) · Neurology · doi:10.1212/wnl.47.3.644 · Cited by 195
Progress in Parkinson's disease—Where do we stand?
Toulouse, A., & Sullivan, A. M. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.05.003 · Cited by 197
Molecular mechanisms underlying protective effects of quercetin against mitochondrial dysfunction and progressive dopaminergic neurodegeneration in cell culture and MitoPark transgenic mouse models of Parkinson's Disease
Ay, M., Luo, J. D., Langley, M. R., Jin, H., Anantharam, V., Kanthasamy, A., & Kanthasamy, A. G. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14033 · Cited by 191
The use of alternative therapies by patients with Parkinson’s disease
Rajendran, P. R., Thompson, R. E., & Reich, S. G. (2001) · Neurology · doi:10.1212/wnl.57.5.790 · Cited by 180
Vitamin E and Neurodegenerative Disorders Associated with Oxidative Stress
Butterfield, D. A., Castegna, A., Drake, J., Scapagnini, G., & Calabrese, V. (2002) · Nutritional Neuroscience · doi:10.1080/10284150290028954 · Cited by 172
Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice
Lan, J., & Jiang, D. (1997) · Journal of Neural Transmission · doi:10.1007/bf01277665 · Cited by 160
Oxidative Stress in Parkinson’s Disease: Potential Benefits of Antioxidant Supplementation
Percário, S., Barbosa, A. D. S., Varela, E. L. P., Gomes, A. R. Q., Ferreira, M. E. S., Moreira, T. D. N. A., & Dolabela, M. F. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2360872 · Cited by 158
Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress
Jurcău, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111847 · Cited by 152
Neuroprotective adaptations in hibernation: therapeutic implications for ischemia-reperfusion, traumatic brain injury and neurodegenerative diseases
Drew, K. L., Rice, M. E., Kuhn, T. B., & Smith, M. A. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00628-1 · Cited by 150
The Promise of Neuroprotective Agents in Parkinson?s Disease
Seidl, S. E., & Potashkin, J. A. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00068 · Cited by 145
Free Radicals in Biology: Sources, Reactivities, and Roles in the Etiology of Human Diseases
Kehrer, J. P., & Smith, C. V. (1994) · Elsevier eBooks · doi:10.1016/b978-0-08-057168-3.50008-4 · Cited by 137
Vitamin E and neurodegenerative diseases
Ricciarelli, R., Argellati, F., Pronzato, M. A., & Domenicotti, C. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2007.01.004 · Cited by 128
The Role of Vitamins in Neurodegenerative Disease: An Update
Nand, S., Singh, P., Steinbusch, H. W. M., Vamanu, E., Ashraf, G. M., & Singh, M. P. (2021) · Biomedicines · doi:10.3390/biomedicines9101284 · Cited by 126
The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis
Enochs, W. S., Sarna, T., Zecca, L., Riley, P. A., & Swartz, H. M. (1994) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02260963 · Cited by 116
Anti-Oxidants in Parkinson's Disease Therapy: A Critical Point of View
Filograna, R., Beltramini, M., Bubacco, L., & Bisaglia, M. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666151030102718 · Cited by 110
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management.
Kidd, P. M. (2000) · PubMed · Cited by 110
Benefits of Vitamins in the Treatment of Parkinson’s Disease
Zhao, X., Zhang, M., Li, C., Jiang, X., Su, Y., & Zhang, Y. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9426867 · Cited by 106
Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: Relevance to Parkinson's disease
Zeevalk, G. D., Manzino, L., Sonsalla, P. K., & Bernard, L. P. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.004 · Cited by 103
Vitamin E therapy in Parkinson's disease
Fariss, M. W. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00158-6 · Cited by 100
High doses of vitamin E in the treatment of disorders of the central nervous system in the aged
Vatassery, G. T., Bauer, T. A., & Dysken, M. W. (1999) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/70.5.793 · Cited by 97
Role of Dietary Supplements in the Management of Parkinson’s Disease
Ciulla, M., Marinelli, L., Cacciatore, I., & Stefano, A. D. (2019) · Biomolecules · doi:10.3390/biom9070271 · Cited by 96
No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
Ahlskog, J. E., Uitti, R. J., Low, P. A., Tyce, G. M., Nickander, K. K., Petersen, R. C., & Kokmen, E. (1995) · Movement Disorders · doi:10.1002/mds.870100507 · Cited by 90
Tocopherol (Vitamin E) in Alzheimer???s Disease and Other Neurodegenerative Disorders
Berman, K., & Brodaty, H. (2004) · CNS Drugs · doi:10.2165/00023210-200418120-00005 · Cited by 89
Role of the antioxidant ascorbate in hibernation and warming from hibernation
Drew, K. L., Tøien, Ø., Rivera, P., Smith, M. A., Perry, G. L., & Rice, M. E. (2002) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/s1532-0456(02)00118-7 · Cited by 89
Mitochondrial Inhibition and Oxidative Stress: Reciprocating Players in Neurodegeneration
Zeevalk, G. D., Bernard, L. P., Song, C., Gluck, M. J., & Ehrhart, J. (2005) · Antioxidants and Redox Signaling · doi:10.1089/ars.2005.7.1117 · Cited by 89
Short-Term Supplementation with Plant Extracts Rich in Flavonoids Protect Nigrostriatal Dopaminergic Neurons in a Rat Model of Parkinson's Disease
Datla, K. P., Zbarsky, V., Rai, D., Parkar, S., Osakabe, N., Aruoma, O. I., & Dexter, D. T. (2007) · Journal of the American College of Nutrition · doi:10.1080/07315724.2007.10719621 · Cited by 83
Antioxidant Therapeutics in Parkinson’s Disease: Current Challenges and Opportunities
Duarte-Jurado, A. P., Gopar‐Cuevas, Y., Cárdenas, O. S., Loera‐Arias, M. D. J., Montes‐de‐Oca‐Luna, R., García‐García, A., & Rodríguez‐Rocha, H. (2021) · Antioxidants · doi:10.3390/antiox10030453 · Cited by 83
Mitochondrial medicine for neurodegenerative diseases
Du, H., & Yan, S. S. (2010) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2010.01.004 · Cited by 82
The Effect of Ascorbic Acid on the Pharmacokinetics of Levodopa in Elderly Patients with Parkinson Disease
Nagayama, H., Hamamoto, M., Ueda, M., Nito, C., Yamaguchi, H., & Katayama, Y. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000150865.21759.bc · Cited by 80
Risk Factors for Alzheimer’s Disease: Role of Multiple Antioxidants, Non-Steroidal Anti-inflammatory and Cholinergic Agents Alone or in Combination in Prevention and Treatment
Prasad, K. N., Cole, W. C., & Prasad, K. C. (2002) · Journal of the American College of Nutrition · doi:10.1080/07315724.2002.10719249 · Cited by 76
Simultaneous determination of carotenoids, tocopherols, and γ‐oryzanol in crude rice bran oil by liquid chromatography coupled to diode array and mass spectrometric detection employing silica C30 stationary phases
Stöggl, W., Huck, C. W., Wongyai, S., Scherz, H., & Bonn, G. K. (2005) · Journal of Separation Science · doi:10.1002/jssc.200500176 · Cited by 76
Multiple Antioxidants in the Prevention and Treatment of Alzheimer Disease: Analysis of Biologic Rationale
Prasad, K. N., Hovland, A. R., Cole, W. C., Prasad, K. C., Nahreini, P., Edwards‐Prasad, J., & Andreatta, C. P. (2000) · Clinical Neuropharmacology · doi:10.1097/00002826-200001000-00002 · Cited by 75
Oxygen radical detoxification processes during aging:The functional importance of melatonin
Reiter, R. J. (1995) · Aging Clinical and Experimental Research · doi:10.1007/bf03324344 · Cited by 71
Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2
Pham, D. Q., & Plakogiannis, R. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1g271 · Cited by 70
Multiple antioxidants in the prevention and treatment of neurodegenerative disease: analysis of biologic rationale
Prasad, K. N., Cole, W. C., Hovland, A. R., Prasad, K. C., Nahreini, P., Kumar, B., Edwards‐Prasad, J., & Andreatta, C. P. (1999) · Current Opinion in Neurology · doi:10.1097/00019052-199912000-00017 · Cited by 70
Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough
Löhle, M., & Reichmann, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.025 · Cited by 70
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines
Zádori, D., Klivènyi, P., Plangár, I., Toldi, J., & Vécsei, L. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01237.x · Cited by 68
Free radicals after painful stimulation are influenced by antioxidants and analgesics.
Rokyta, R., Holecek, Pekárková, I., Krejcová, J., Ráček, J., Trefil, L., & Yamamotová, A. (2003) · PubMed · Cited by 65
Free radicals in Alzheimer’s dementia: currently available therapeutic strategies
Rösler, M., Retz, W., Thome, J., & Riederer, P. F. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-7508-8_21 · Cited by 60
Analysis of vitamin E in food and phytopharmaceutical preparations by HPLC and HPLC-APCI-MS-MS
Stöggl, W., Huck, C. W., Scherz, H., Popp, M. A., & Bonn, G. K. (2001) · Chromatographia · doi:10.1007/bf02492241 · Cited by 59
Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson’s disease
Naoi, M., Maruyama, W., & Shamoto‐Nagai, M. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02150-w · Cited by 58
Protection Against Parkinson’s Disease Progression: Clinical Experience
LeWitt, P. A., & Taylor, D. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.01.007 · Cited by 57
Antioxidant strategies in protection against neurodegenerative disorders
Tan, D.-X., Manchester, L. C., Sainz, R. M., Mayo, J. C., Alvares, F. L., & Reiter, R. J. (2003) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.13.10.1513 · Cited by 57
Parkinson's Disease: Mitochondrial Molecular Pathology, Inflammation, Statins, and Therapeutic Neuroprotective Nutrition
KONES, R. J. (2010) · Nutrition in Clinical Practice · doi:10.1177/0884533610373932 · Cited by 57
Lipophilic antioxidants in neurodegenerative diseases
Chang, K., Cheng, M., Chiang, M.-C., & Chen, C. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.06.031 · Cited by 59
Niacin and Butyrate: Nutraceuticals Targeting Dysbiosis and Intestinal Permeability in Parkinson’s Disease
Karunaratne, T. B., Okereke, C., Seamon, M., Purohit, S. B., Wakade, C. G., & Sharma, A. (2020) · Nutrients · doi:10.3390/nu13010028 · Cited by 55
Potential Future Neuroprotective Therapies for Neurodegenerative Disorders and Stroke
Tarawneh, R. M., & Galvin, J. E. (2010) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2009.12.003 · Cited by 54
Metabolite Profiling Based on Lipophilic Compounds for Quality Assessment of Perilla (Perilla frutescens) Cultivars
Kim, J. K., Park, S.-Y., Na, J.-K., Seong, E. S., & Yu, C. Y. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf204977x · Cited by 45
Parkinsons Disease: Genetics and Beyond
Inamdar, N., Arulmozhi, D. K., Tandon, A., & Bodhankar, S. L. (2007) · Current Neuropharmacology · doi:10.2174/157015907780866893 · Cited by 46
Hydroxytyrosol induces phase II detoxifying enzyme expression and effectively protects dopaminergic cells against dopamine- and 6-hydroxydopamine induced cytotoxicity
Yu, G., Deng, A., Tang, W., Junzhi, M., Yuan, C., & Ma, J. (2016) · Neurochemistry International · doi:10.1016/j.neuint.2016.03.005 · Cited by 44
Exploring multifunctional antioxidants as potential agents for management of neurological disorders
Sindhu, R. K., Kaur, P., Kaur, P., Singh, H., Batiha, G. E., & Verma, I. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-17667-0 · Cited by 44
Qualitative versus quantitative caloric intake: are they equivalent paths to successful aging?
Casadesús, G., Shukitt‐Hale, B., & JOSEPH, J. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00079-9 · Cited by 40
Medical treatment of Parkinson’s disease
Fahn, S. (1998) · Journal of Neurology · doi:10.1007/pl00007742 · Cited by 38
Self-citation
Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies
Dexter, D. T., Brooks, D. J., Harding, A. E., Burn, D. J., Muller, D. P. R., Goss-Sampson, M. A., Jenner, P. G., & MARSDEN, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410350309 · Cited by 38
Pharmacological Therapy in Parkinson's Disease: Focus on Neuroprotection
Kincses, Z. T., & Vécsei, L. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00150.x · Cited by 39
Evidence for Oxidative Pathways in the Pathogenesis of PD: Are Antioxidants Candidate Drugs to Ameliorate Disease Progression?
Leathem, A., Ortíz, T., Dennis, J. M., & Witting, P. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136923 · Cited by 36
Treatment of motor dysfunction in Parkinson's disease: an overview
Thobois, S., Delamarre-Damier, F., & Derkinderen, P. (2005) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2005.02.002 · Cited by 36
Effects of antioxidants on auditory nerve function and survival in deafened guinea pigs
Maruyama, J., Yamagata, T., Ulfendahl, M., Bredberg, G., Altschuler, R. A., & Miller, J. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.012 · Cited by 35
Pharmacologic Management of Alzheimer Disease Part II: Antioxidants, Antihypertensives, and Ergoloid Derivatives
Flynn, B. L., & Ranno, A. E. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.17172 · Cited by 35
Boosting mitochondrial health to counteract neurodegeneration
Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36
The antioxidant drink “effective microorganism-X (EM-X)” pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson’s disease
Datla, K. P., Bennett, R. D., Zbarsky, V., Ke, B., Liang, Y.-F., Hig, T., Bahorun, T., Aruoma, O. I., & Dexter, D. T. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357023222 · Cited by 34
An Integrated Biochemical, Proteomics, and Metabolomics Approach for Supporting Medicinal Value of Panax ginseng Fruits
Kim, S. W., Gupta, R., Lee, S. H., Min, C. W., Agrawal, G. K., Rakwal, R., Kim, J. B., Jo, I.-H., Park, S.-Y., Kim, J. K., et al. (2016) · Frontiers in Plant Science · doi:10.3389/fpls.2016.00994 · Cited by 33
Reduction of lipid peroxidation in different brain regions by a combination of ?-tocopherol and ascorbic acid
Bano, S., & Parihar, M. S. (1997) · Journal of Neural Transmission · doi:10.1007/bf01294728 · Cited by 31
The Implementation of Acute versus Chronic Animal Models for Treatment Discovery in Parkinson's Disease
Willis, G. L., & Kennedy, G. A. (2004) · Reviews in the Neurosciences · doi:10.1515/revneuro.2004.15.1.75 · Cited by 30
Plasma levels of vitamin E in Parkinson's disease
Nicoletti, G., Crescibene, L., Scornaienchi, M., Bastone, L., Bagalà, A., Napoli, I., Caracciolo, M., & Quattrone, A. (2001) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(01)00092-9 · Cited by 30
Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures
Ehrhart, J., & Zeevalk, G. D. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01954.x · Cited by 30
Neuroprotective effect of NXP031 in the MPTP-induced Parkinson's disease model
Song, M. K., Lee, J. H., Kim, J.-I., Kim, J. H., Hwang, S., Kim, Y.-S., & Kim, Y. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135425 · Cited by 29
Vitamin E as a protective antioxidant in progressive renal failure
Fryer, M. J. (2000) · Nephrology · doi:10.1046/j.1440-1797.2000.00504.x · Cited by 29
Systematic Surveys of Iron Homeostasis Mechanisms Reveal Ferritin Superfamily and Nucleotide Surveillance Regulation to be Modified by PINK1 Absence
Key, J., Şen, N.-E., Arsović, A., Krämer, S., Hülse, R., Khan, N. N., Meierhofer, D., Gispert, S., Koepf, G., & Auburger, G. W. J. (2020) · Cells · doi:10.3390/cells9102229 · Cited by 29
Experience with tranylcypromine in early Parkinson’s disease
Fahn, S., & Chouinard, S. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6499-0_6 · Cited by 27
Self-citation
Longevity effect of chromium picolinate — ‘rejuvenation’ of hypothalamic function?
McCarty, M. F. (1994) · Medical Hypotheses · doi:10.1016/0306-9877(94)90076-0 · Cited by 27
Mechanisms of Atherosclerosis: Role of LDL Oxidation
Reaven, P. D. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-1833-4_9 · Cited by 25
Circulating Antioxidants as Determinants of the Rate of Biological Aging in Pigtailed Macaques (Macaca nemestrina)
Short, R., Williams, D. D., & Bowden, D. M. (1997) · The Journals of Gerontology Series A · doi:10.1093/gerona/52a.1.b26 · Cited by 24
Controlled and Impaired Mitochondrial Quality in Neurons: Molecular Physiology and Prospective Pharmacology
Matić, I., Strobbe, D., Frison, M., & Campanella, M. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.021 · Cited by 23
Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice
Lazzarini, M., Salum, C., & Bel, E. A. D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2222-6 · Cited by 21
Estudio caso-control de marcadores de estrés oxidativo y metabolismo del hierro plasmático en la enfermedad de Parkinson
Ilundáin, R. L., Valls, J. V. F., Rueda, J. J. V., Guerrero, D., & Fraile, P. (2001) · Revista Española de Salud Pública · doi:10.1590/s1135-57272001000100006 · Cited by 21
Potential prevention and treatment of neurodegenerative disorders by olive polyphenols and hidrox
Ontario, M. L., Siracusa, R., Modafferi, S., Scuto, M. C., Sciuto, S., Greco, V., Bertuccio, M. P., Salinaro, A. T., Crea, R., Calabrese, E. J., et al. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111637 · Cited by 20
Comparison of Environmental and Genetic Factors for Parkinson’s Disease between Chinese and Caucasians
Chan, D. K. Y., Cordato, D. J., Bui, T., Mellick, G. D., & Woo, J. (2004) · Neuroepidemiology · doi:10.1159/000073970 · Cited by 20
Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain
Ren, Y., Nishida, Y., Yoshimi, K., Yasuda, T., Jishage, K., Uchihara, T., Yokota, T., Mizuno, Y., & Mochizuki, H. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03994.x · Cited by 19
Influence of exercise-induced oxidative stress on the central nervous system
Somani, S. M., & Husain, K. M. (2000) · Elsevier eBooks · doi:10.1016/b978-044482650-3/50026-2 · Cited by 19
A novel synthetic isothiocyanate ITC-57 displays antioxidant, anti-inflammatory, and neuroprotective properties in a mouse Parkinson’s disease model
Lee, J. A., Son, H. J., Kim, J. H., Park, K. D., Shin, N., Kim, H. R., Kim, E., Kim, D. J., & Hwang, O. (2016) · Free Radical Research · doi:10.1080/10715762.2016.1223293 · Cited by 17
Navigating the dichotomy of reactive oxygen, nitrogen, and sulfur species: detection strategies and therapeutic interventions
Baruah, P., Padhi, D., Moorthy, H., Ramesh, M., & Govindaraju, T. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00006h · Cited by 16

Authors: Fahn, S.
Affiliations: Columbia University Irving Medical Center (US)
Corresponding author: Fahn, Stanley
Venue: Annals of Neurology
Publisher: Wiley
Published: 1992
Volume: 32
Issue: S1
Pages: S128-S132
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410320722
OpenAlex: W2112404451
Cited by: 211
References: 14
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 8 · 2022: 7 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 2 · 2017: 4 · 2016: 6 · 2015: 3 · 2014: 9 · 2013: 4 · 2012: 3
FWCI: 14.62
Type: journal article
Language: en
Open access: closed
Licence: doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 8644 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Coenzyme Q10 studies and effects
Health Sciences › Medicine › Biochemistry (medical) › Antioxidant Activity and Oxidative Stress
Keywords: Parkinson's disease, alpha-tocopherol, vitamin C, antioxidants, disease progression, early-stage Parkinson's disease, amantadine, anticholinergic agents
MeSH terms: Adult, Aged, Ascorbic Acid, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Parkinson Disease, Pilot Projects, Research Design, Vitamin E

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks